CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 110 enrolled
Drug / intervention
Oral bovine type II collagendrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00000401
NCT00000401Phase 2Completed
CompareCT.gov

Open Label Multicenter Induction of CII Tolerance in Patients With Rheumatoid Arthritis

University of Tennessee·interventional·Posted Nov 4, 1999·Updated May 29, 2013

In Brief

A Phase 2 clinical trial evaluating Oral bovine type II collagen for Rheumatoid Arthritis. Completed, enrolled 110 participants across 2 sites.

Detailed Summary

Rheumatoid arthritis (RA) is an autoimmune disease characterized by swelling and inflammation of the joints. In RA, the immune system attacks a person's own cells inside joints, eventually leading to joint damage and disability. This study will determine if oral bovine type II collagen (bovine CII) will lead to decreased joint inflammation in RA patients.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsRheumatoid Arthritis
CountriesUnited States
CollaboratorsNational Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)

Timeline

Phase 2CompletedFinished
19992000200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedNov 4, 1999
Enrollment StartJul 1, 1999
Primary CompletionAug 1, 2005
TodayJul 2, 2026
Enrollment to primary: 6.1 yearsPosted 26.7 years ago

Interventions

Oral bovine type II collagendrug

Drug can be interrupted or stopped for suspected adverse events.